<DOC>
	<DOCNO>NCT01542788</DOCNO>
	<brief_summary>This multicenter study evaluate subject chronic genotype 2 3 HCV infection interferon ( IFN ) ineligible , IFN intolerant unwilling take IFN . Participants randomize 3:1 ratio receive sofosbuvir ( SOF ) +ribavirin ( RBV ) , placebo match SOF+placebo match RBV . Randomization stratify presence/absence cirrhosis . Approximately 20 % participant may evidence cirrhosis screening .</brief_summary>
	<brief_title>Sofosbuvir + Ribavirin 12 Weeks Subjects With Chronic Genotype 2 3 Hepatitis C Infection Who Are Interferon Intolerant , Interferon Ineligible Unwilling Take Interferon</brief_title>
	<detailed_description>Participants randomize placebo arm complete schedule study procedure eligible receive active SOF+RBV open-label Study GS-US-334-0109 . Participants achieve sustain virologic response ( SVR ) eligible enrollment Sequence Registry Study GS-US-248-0123 . The purpose Sequence Registry Study monitor persistence resistant mutation 3 year . Participants achieve SVR eligible enrollment SVR Registry Study GS-US-248-0122 . The purpose SVR Registry Study evaluate durability SVR 3 year treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Infection HCV genotype 2 3 Cirrhosis determination Subject meet one follow classification : 1 . IFN unwilling 2 . IFN ineligible 3 . IFN intolerant Screening laboratory value within define threshold Subject treat investigational drug device within 30 day Screening visit Use highly effective contraception method female childbearing potential sexually active male Prior exposure directacting antiviral target HCV nonstructural protein ( NS ) 5B polymerase Pregnant nursing female male pregnant female partner Current prior history clinical hepatic decompensation History clinicallysignificant illness major medical disorder may interfere subject treatment , assessment compliance protocol Excessive alcohol ingestion significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HCV genotype 2 ( GT-2 )</keyword>
	<keyword>HCV genotype 3 ( GT-3 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Interferon intolerant</keyword>
	<keyword>Interferon ineligible</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
</DOC>